Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Almotriptan Malate Intermediates: Almotriptan Malate CAS 181183-52-8 1-((4-Hydrazinylbenzyl)sulfonyl)pyrrolidine Hydrochloride CAS 334981-11-2 4-[(1-Pyrrolidinylsulfonyl)methyl]aniline CAS 334981-10-1 1-[(4-Nitrophenylmethyl)sulfonyl]pyrrolidine CAS 340041-91-0 4-Chlorobutyraldehyde Diethyl Acetal CAS 6139-83-9| Item | Specifications |
| Appearance | White to Faint Yellow Crystalline Powder |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <0.50% |
| Residue on Ignition | <0.50% |
| Max Single Impurity | <0.50% |
| Total Impurities | <1.00% |
| Heavy Metals | <20ppm |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Almotriptan Aniline Precursor |
Description:
Specifications:
Package & Storage:
| Chemical Name | 4-[(1-Pyrrolidinylsulfonyl)methyl]aniline |
| Synonyms | 1-[(4-Aminobenzyl)sulfonyl]pyrrolidine; Almotriptan Aniline Precursor |
| CAS Number | 334981-10-1 |
| CAT Number | RF-PI1948 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C11H16N2O2S |
| Molecular Weight | 240.32 |
| Melting Point | 170.0 to 176.0℃ |
| Density | 1.31 |
| Solubility | Slightly Soluble in Toluene |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
4-[(1-Pyrrolidinylsulfonyl)methyl]aniline (CAS: 334981-10-1) is an intermediate in the preparation of Almotriptan Malate (CAS: 181183-52-8), Almotriptan Aniline Precursor. Almotriptan Malate is a kind of triptan drug which can be used for the treatment of migraine headaches. Almotriptan is belong to a drug category of selective serotonin receptor agonists. Almotriptan has a high and specificity affinity for serotonin 5-HT receptors, further leading to vascoconstriction of the brain blood vessel and affecting the redistribution of blood flow. These effects stop pain signals from being sent to the brain, and further suppressing the release of certain natural substances which cause pain, nausea and other migraine symptoms. However, Almotriptan doesn’t prevent migraine attacks. Almotriptan, marketed in 2000, has the highest oralbioavailability among all triptans. Almotriptan is metabolizedby both MAO-A and CYP3A4, thus has a more favorableside effects profile when compared with Sumatriptan.
